{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:56:25Z","timestamp":1790776585981,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Boosted atazanavir (ATV\/r) is associated with clinical jaundice, which may affect ART adherence. However, the prevalence of clinical jaundice among people on ATV\/r and its association with ART adherence is unknown in Uganda.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a cross-sectional study among 236 adult patients on ATV\/r at the Infectious Disease Institute. Clinical jaundice was assessed by self-report and observation; ART adherence was measured using the 8-item Morisky scale.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Period prevalence of clinical jaundice was 31.8%, while point prevalence was 21.1%. While 8.5% had poor adherence, clinical jaundice was a significant predictor of poor adherence (adjusted odds ratio\u2009=\u20093.03, 95% CI: 1.18\u20137.76,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinical jaundice is common among patients on ATV\/r in Uganda and is associated with poor ART adherence. Strengthening pre-ATV\/r (pre-switch) counselling and exploring safer regimen alternatives are required to improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-026-00908-y","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:34:26Z","timestamp":1783168466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brief communication: clinical jaundice is associated with poor adherence to boosted atazanavir among adults in an HIV clinic in Kampala, Uganda"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2065-748X","authenticated-orcid":false,"given":"Angella","family":"Nabakooza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5784-9497","authenticated-orcid":false,"given":"Sharon Kitibwakye","family":"Nakamanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Agnes","family":"Laker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Katana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noela","family":"Owarwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Lwanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Lamorde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-9572","authenticated-orcid":false,"given":"Freddy Kitutu","family":"Eric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"1","key":"908_CR1","first-page":"43","volume":"19","author":"II Bartlett","year":"2001","unstructured":"Bartlett II, Kotrlik JE, J.W. and, Higgins CC. Organizational research: Determing appropriate sample size in survey research. Inform Technol Learn Perform J. 2001;19(1):43.","journal-title":"Inform Technol Learn Perform J"},{"issue":"11","key":"908_CR2","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1517\/17425250903321514","volume":"5","author":"D Bentu-Ferrer","year":"2009","unstructured":"Bentu-Ferrer D, et al. Clinical pharmacology, efficacy and safety of atazanavir: A review. Expert Opin Drug Metabolism Toxicol. 2009;5(11):1455\u201368. https:\/\/doi.org\/10.1517\/17425250903321514.","journal-title":"Expert Opin Drug Metabolism Toxicol"},{"key":"908_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/5415298","volume":"2017","author":"M Biset Ayalew","year":"2017","unstructured":"Biset Ayalew M. Mortality and its predictors among HIV infected patients taking antiretroviral treatment in Ethiopia: A systematic review. AIDS Res Treat. 2017;2017:1\u201310. https:\/\/doi.org\/10.1155\/2017\/5415298.","journal-title":"AIDS Res Treat"},{"issue":"3","key":"908_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1089\/aid.2012.0233","volume":"29","author":"E Bissio","year":"2013","unstructured":"Bissio E, Lopardo GD. Incidence of hyperbilirubinemia and jaundice due to Atazanavir in a cohort of Hispanic patients. AIDS Res Hum Retroviruses. 2013;29(3):415\u20137. https:\/\/doi.org\/10.1089\/aid.2012.0233.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"1","key":"908_CR5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12981-018-0214-y","volume":"16","author":"D Bukenya","year":"2019","unstructured":"Bukenya D, et al. What causes non-adherence among some individuals on long term antiretroviral therapy? Experiences of individuals with poor viral suppression in Uganda. AIDS Res Therapy. 2019;16(1):2. https:\/\/doi.org\/10.1186\/s12981-018-0214-y.","journal-title":"AIDS Res Therapy"},{"issue":"4","key":"908_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpt.269","volume":"99","author":"RS Gammal","year":"2016","unstructured":"Gammal RS, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing. Clin Pharmacol Ther. 2016;99(4):363\u20139. https:\/\/doi.org\/10.1002\/cpt.269.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"908_CR7","doi-asserted-by":"publisher","first-page":"e0276411","DOI":"10.1371\/journal.pone.0276411","volume":"18","author":"LD Hlophe","year":"2023","unstructured":"Hlophe LD, et al. Barriers and facilitators to anti-retroviral therapy adherence among adolescents aged 10 to 19 years living with HIV in sub-Saharan Africa: A mixed-methods systematic review and meta-analysis. PLoS ONE. 2023;18(5):e0276411. https:\/\/doi.org\/10.1371\/journal.pone.0276411.","journal-title":"PLoS ONE"},{"issue":"2","key":"908_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1469-1809.2010.00638.x","volume":"75","author":"LJ Horsfall","year":"2011","unstructured":"Horsfall LJ, et al. Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations. Ann Hum Genet. 2011;75(2):236\u201346. https:\/\/doi.org\/10.1111\/j.1469-1809.2010.00638.x.","journal-title":"Ann Hum Genet"},{"issue":"4 Suppl 3","key":"908_CR9","doi-asserted-by":"publisher","first-page":"19579","DOI":"10.7448\/ias.17.4.19579","volume":"17","author":"V Kanestri","year":"2014","unstructured":"Kanestri V, et al. Clinical significance of the UGT1A1*28 allele detection in HIV-infected patients. J Int AIDS Soc. 2014;17(4 Suppl 3):19579. https:\/\/doi.org\/10.7448\/ias.17.4.19579.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"908_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40359-018-0249-9","volume":"6","author":"R-D Kocalevent","year":"2018","unstructured":"Kocalevent R-D, et al. Social support in the general population: standardization of the Oslo social support scale (OSSS-3). BMC Psychol. 2018;6(1):1\u20138. https:\/\/doi.org\/10.1186\/S40359-018-0249-9.","journal-title":"BMC Psychol"},{"issue":"5","key":"908_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1089\/apc.2011.0092","volume":"26","author":"C McDonald","year":"2012","unstructured":"McDonald C, et al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir\/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDs. 2012;26(5):259\u201364. https:\/\/doi.org\/10.1089\/apc.2011.0092.","journal-title":"AIDS Patient Care STDs"},{"issue":"11","key":"908_CR12","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1371\/journal.pmed.0030438","volume":"3","author":"EJ Mills","year":"2006","unstructured":"Mills EJ, et al. Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3(11):2039\u201364. https:\/\/doi.org\/10.1371\/journal.pmed.0030438.","journal-title":"PLoS Med"},{"issue":"3","key":"908_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s12529-012-9243-4","volume":"20","author":"Y Molina","year":"2013","unstructured":"Molina Y, et al. The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, validation and use across neurological conditions. Int J Behav Med. 2013;20(3):450\u201360. https:\/\/doi.org\/10.1007\/s12529-012-9243-4.","journal-title":"Int J Behav Med"},{"key":"908_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1265-5","author":"N Nabukeera-Barungi","year":"2015","unstructured":"Nabukeera-Barungi N, et al. Adherence to antiretroviral therapy and retention in care for adolescents living with HIV from 10 districts in Uganda. BMC Infect Dis. 2015. https:\/\/doi.org\/10.1186\/s12879-015-1265-5.","journal-title":"BMC Infect Dis"},{"key":"908_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/PGPM.S107152","volume":"10","author":"P Panagopoulos","year":"2017","unstructured":"Panagopoulos P, et al. Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele. Pharmacogenomics Personalized Med. 2017;10:205\u20138. https:\/\/doi.org\/10.2147\/PGPM.S107152.","journal-title":"Pharmacogenomics Personalized Med"},{"issue":"8","key":"908_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.mpsur.2020.06.008","volume":"38","author":"R Ravindran","year":"2020","unstructured":"Ravindran R. Jaundice. Surg (United Kingdom). 2020;38(8):446\u201352. https:\/\/doi.org\/10.1016\/j.mpsur.2020.06.008.","journal-title":"Surg (United Kingdom)"},{"issue":"3","key":"908_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/infdis\/jis690","volume":"207","author":"HJ Ribaudo","year":"2013","unstructured":"Ribaudo HJ, et al. Impact of UGT1A1 gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS clinical trials group study A5202. J Infect Dis. 2013;207(3):420\u20135. https:\/\/doi.org\/10.1093\/infdis\/jis690.","journal-title":"J Infect Dis"},{"issue":"10","key":"908_CR19","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1177\/003591576906201005","volume":"62","author":"JP Shillingford","year":"1969","unstructured":"Shillingford JP, Aitken CB. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969;62(10):989. https:\/\/doi.org\/10.1177\/003591576906201005.","journal-title":"Proc R Soc Med"},{"key":"908_CR20","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200408150-00003","author":"K Squires","year":"2004","unstructured":"Squires K, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. JAIDS J Acquir Immune Defic Syndr. 2004. https:\/\/doi.org\/10.1097\/00126334-200408150-00003.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"9","key":"908_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1089\/aid.2011.0261","volume":"28","author":"L Turatti","year":"2012","unstructured":"Turatti L, et al. Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in Southern Brazil. AIDS Res Hum Retroviruses. 2012;28(9):815\u20138. https:\/\/doi.org\/10.1089\/aid.2011.0261.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"908_CR22","unstructured":"Uganda Ministry of Health. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. Kampala: Ministry of Health, Uganda. 2022."},{"issue":"3","key":"908_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00126334-200311010-00004","volume":"34","author":"S Weiser","year":"2003","unstructured":"Weiser S, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. JAIDS J Acquir Immune Defic Syndr. 2003;34(3):281\u20138. https:\/\/doi.org\/10.1097\/00126334-200311010-00004.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"issue":"1","key":"908_CR24","first-page":"59","volume":"15","author":"Marie Krousel-Wood","year":"2009","unstructured":"Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009 Jan;15(1):59-66.","journal-title":"The American Journal of Managed Care"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-026-00908-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00908-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00908-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:04:33Z","timestamp":1790773473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12981-026-00908-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["908"],"URL":"https:\/\/doi.org\/10.1186\/s12981-026-00908-y","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research and ethics committees at Makerere University School of Health Sciences, Uganda National Council of Science and Technology reviewed and approved the study. Informed consent was obtained from all the research participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"93"}}